Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients
Sponsor: University of California, San Francisco
Summary
To raise the standard of care, improve the overall patient experience and streamline practice flow, Eyenovia has developed an innovative mydriatic to be delivered as a microdose by a specialized dispenser. While still achieving effective pupil dilation, MydCombi has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery. The proposed study hopes to demonstrate the non-inferiority of using MydCombi to achieve pupillary dilation in patients compared to standard of care eye drops.
Key Details
Gender
All
Age Range
2 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2024-09-30
Completion Date
2024-12-31
Last Updated
2024-09-19
Healthy Volunteers
No
Conditions
Interventions
MydCombi Device
ophthalmic spray
MydCombi Drug
Tropicamide 1% and phenylephrine HCl 2.5%
Locations (1)
University of California, San Francisco
San Francisco, California, United States